HNN 3.0
HEALTH-NCP-NET

Health NCP Net

InfoDay Cluster 1 "Health"
Q&A on Calls 2023

www.healthncp.net

INTRODUCTION AND BACKGROUND

On January 19th, 2023, a virtual Horizon Europe Info Day was held for the health cluster by the European Commission. This Info Day aimed to inform (potential) applicants about topics included in the Cluster 1 'Health' work programme of 2023.

The European Commission has published the slides and videos of the topic presentations and the questions and answers (Q&A) online.

This document prepared by NCPs will give you the links to all topic presentations and Q&A sessions including the exact time in the video where the questions are answered.

The aim of this document is to help Health NCPs provide their applicants with the best possible advice and support and to assist applicants in preparing a high-quality application.
This document is provided for information only. It has been written as part of the HNN 3.0 project, a Coordination and Support Action funded by the European Commission, with the goal to improve and support the professionalization of the services rendered by Cluster 1 – Health NCPs across Europe, helping for a simpler access to different health related Horizon Europe calls, lowering the entry barriers for newcomers and raising the average quality of the submitted proposals.

CONTENTS

Destination 1 - Staying healthy in a rapidly changing society

[Watch Presentation](#) of Destination 1 Topics; [Watch the whole Q&A](#) on Destination 1

HORIZON-HLTH-2023-STAYHLTH-01-01: The Silver Deal - Person-centred health and care in European regions

	Question	Link to answer
1.	Are funds allocated for the preparation of the proposal?	09:17
2.	Is there any TRL range for the 01-01 RIA?	09:36
3.	Would the involvement of large companies (industry) be looked upon favourable by the evaluators or should the focus be on SMEs?	10:36
4.	Is the development of new technological solutions (wearables) in the scope, or is it more about the deployment of existing technological and digital solutions?	11:32

Destination 2. Living and working in a health-promoting environment

[Watch Presentation](#) of Destination 2 Topics; [Watch the whole Q&A](#) on Destination 2

General Questions

	Question	Link to answer
1.	Award criteria - Proposals not reaching all 3 thresholds (excel, impact, implementation) will not be considered for funding?	11:28
2.	Are proposals expected to include a description of potential joint activities to be developed in collaboration with other projects selected under the same call?	22:40
3.	The call requests that proposals should allocate a budget for networking and joint activities. What sum do you consider as adequate?	25:28

HORIZON-HLTH-2023-ENVHLTH-02-01: Planetary health: understanding the links between environmental degradation and health impacts

	Question	Link to answer
1.	Is it possible to address in the proposals only part of the activities listed from a perspective of only part of the planetary health components?	15:01
2.	Planetary health: is the development of sensors to evaluate the impact of environment degradation in the scope, or are you expecting existing solutions?	27:32

HORIZON-HLTH-2023-ENVHLTH-02-02: Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)

	Question	Link to answer
1.	Do all the health impacts considered in the proposals need to be related to changes in working environments resulting from the Covid pandemics?	8:27

	Question	Link to answer
2.	How should proposals contribute to New European Bauhaus (NEB) initiative? how and with whom concretely should they interact?	11:45
3.	Which of them would be a better fit fora project using VP for healthcare workers to and reduce the burnout?	16:40
4.	Should proposals focus only on physical health interventions, or do all proposals also need to cover mental health aspects?	20:49
5.	Can proposals extend to health disorders (e.g. back pain)?	23:40
6.	Is it acceptable to focus on one type of profession in one work context or should it be applicable across many work contexts?	24:15
7.	(...) Considering [A disaggregated effects for different socio-economic groups". Can you please elaborate further on how this should be applied?	26:30
8.	ENVHLTH-02-02: can you elaborate on what is expected of activities in relation to the New European Bauhaus initiative in the proposals.	28:18

HORIZON-HLTH-2023-ENVHLTH-02-03: Health impacts of endocrine-disrupting chemicals: bridging science-policy gaps by addressing persistent scientific uncertainties

	Question	Link to answer
1.	Can you elaborate further on the interaction proposals are expected to be developed with JRC? Specifically considering IPCHEM and regulatory feedback?	6:15
2.	It is indicated that projects are expected to be acquainted with the activities of PARC. How and at which stage should this be done?	10:10
3.	Can you please elaborate on the expected role of SSH partnerships in projects funded under this call?	30:25

HORIZON-HLTH-2023-ENVHLTH-02-04: Global coordination of exposome research

	Question	Link to answer
1.	Can you elaborate further on how proposals are expected to facilitate the regulatory use of exposome data?	11:52
2.	How much participation of widening and associated countries is expected for this OSA?	18:50
3.	Can you provide examples of research projects that should be involved in this CSA?	19:36

Destination 3. Tackling diseases and reducing disease burden

Watch Presentation of Destination 3 Topics; Watch the whole Q&A on Destination 3

HORIZON-HLTH-2023-DISEASE-03-01: Novel approaches for palliative and end-of-life care for non-cancer patients

	Question	Link to answer
1.	Does the scope of the topic also cover interventions for the paediatric population?	12:40

Question	Link to answer
2. Should EACH proposal address ALL age groups or can an individual proposal focus on a specific age group.	16:34
3. Is the development of a new wearable (for pain evaluation) up to the proof-of-concept (TRL4-5) in the scope?	17:29
4. Could you please clarify whether proposals should address all age groups of patients or could focus on certain age groups?	18:12
5. Could you please clarify what is meant by re-invigorating and enhancing timely social inclusion of patients?	20:58
6. Can proposals tackling cancer apply?	35:36
7. Where do you see the role of ICT in this call addressing paliative and end of life care?	45:45
8. How should proposals include patients and their families? Should they be directly included as partners?	57:43
9. Can proposals that include both pharmacological and a non-pharmacological intervention apply? Or does it need to be one or the other?	1:09:55
10. Following up the non-pharmacological interventions question - would mental health interventions be eligible?	1:14:38

HORIZON-HLTH-2023-DISEASE-03-03: Interventions in city environments to reduce risk of non-communicable disease (Global Alliance for Chronic Diseases - GACD)

Question	Link to answer
1. Is it necessary to include a member of the GACD in the Consortium in order to be positively evaluated?	15:30
2. Can proposals tackle both themes / interventions mentioned in the topic?	24:49
3. Can rural towns also be included in proposals? Could you give guidance on what constituted a city? (Ex. Number of inhabitants?)	1:15:23
4. Can proposals that aim to reduce tobacco consumption be funded under this topic?	1:17:42

HORIZON-HLTH-2023-DISEASE-03-04: Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

Question	Link to answer
1. What stage of development should the potential antivirals be at? Until what CT stage will you fund?	28:22
2. Is there a list available of diseases considered for topics that refer to diseases with epi/pandemic potential, e.g. topic HORIZON-HLTH-2023-DISEASE-03-04?	36:05
3. What is the expected budget per proposal?	38:19
4. Should each infection listed by the HERA be addressed in one project? Must clinical trials be included in a project?	40:46
5. If clinical trials are a must, should they be Phase I and IIa?	52:15
6. Is it a problem if the clinical trial is just Phase I and Phase IIa isn't included? In other terms: should Phase IIa must be included?	56:25

HORIZON-HLTH-2023-DISEASE-03-05: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks

	Question	Link to answer
1.	Is it possible for 1 proposal to cover the combined coordination of both EU-wide trials and cohorts?	16:57
2.	Will you fund more than one proposal?	29:18
3.	Do the proposals need to buy on previously EU-funded work on clinical trials or cohorts?	38:50
4.	can the proposals work with African partners in the consortium? Or is the aim to build only European networks?	52:48
5.	Do proposals need to contact/liaise with DG HERA before submitting the proposal?	1:01:10

HORIZON-HLTH-2023-DISEASE-03-06: Towards structuring brain health research in Europe

	Question	Link to answer
1.	Whom do you expect to form the consortium in the proposal? Researchers? Policy makers?	22:40
2.	What exactly do you expect to achieve with this topic? What should be the main output?	42:35
3.	Are proposals supposed to perform research? If not - aside from preparing for a potential partnership - what exactly should they do?	1:07:55

HORIZON-HLTH-2023-DISEASE-03-07: Relationship between infections and non-communicable diseases

	Question	Link to answer
1.	Among the infections to be considered by the applicants, is there a prioritization towards those with pandemic potential?	13:19
2.	Will proposals addressing post-COVID condition have an advantage over others during the selection process?	14:40
3.	Is the development of digital medical devices within the scope?	15:50
4.	Does the scope of this call will cover intervention and also whether the scope consider health policy and systems research?	18:49
5.	These proposals should include the topics of SSH and gender equality? Even if they do not deal with directly related topics...?	19:48
6.	Is development of diagnostics, aiming to improve knowledge linking infections with non-communicable diseases, within scope?	22:10
7.	Are projects only on in vitro and in vivo animal models within scope? Or is it required a clinical interface?	26:16
8.	Is it enough to produce a robust evidence base during the project and the actual development tools to diagnose will happen in further projects?	31:20
9.	Are poverty-related & neglected diseases, including TB, HIV, Malaria and neglected tropical diseases included in the scope of HORIZON-HLTH-2023-DISEASE-03-07?	34:00

10. Is the interaction with the microbiome in scope, or only pathological infections?	34:42
11. Is there a maximum or minimum for the budget?	39:46
12. is periodontitis (a severe gum infection) considered as infection?	46:27
13. Can a specific project focus on one NCD type, or should the project be more general in terms of NCDs?	48:54
14. Does this topic have one or two stages? If there are two stages, what must to be delivered on April 13th?	49:20
15. Could be proposed a project to study the link between SARS-CoV-2 infection and long-covid development under this topic?	51:12
16. development of any kind of digital technologies is not a must in this topic – yes or no?	55:28
17. Does the call expect proposals to develop diagnostic methods to detect and eventually prevent aggravation of NCDs by infections?	58:33
18. What is the specific quality of ORCHESTRE that have led to the highlight of this project in the topic?	1:03:48
19. Are proposals working on Neglected Tropical Diseases (NTDs) eligible under this topic?	1:05:56
20. Can the project focus on just long-covid and NCDs?	01:07:11
21. JPND has already funded EU projects exploring the interaction of COVID and neurodegeneration. Can similar projects be funded under this call, too?	1:12:03
22. Projects selected for funding from this topic are not expected to form a cluster with other funded projects – right?	1:16:04

HORIZON-HLTH-2023-DISEASE-03-17: Pandemic preparedness and response: Understanding vaccine induced-immunity

Question	Link to answer
1. Can proposals tackle Ebola virus?	21:37
2. Can proposals address vaccine-induced immunity against just one particular virus of pandemic or epidemic potential?	23:49
3. Could you give us an example about how SSH experts can be included in the projects of this topic?	25:05
4. Can this topic include development of tests of how to measure immunity (e.g. POC tests or other)	30:10
5. Is it necessary for proposals to address how different factors (sex, age) affect the immune response in humans?	32:12
6. Is it necessary for proposals to address how different factors (sex, age) affect the immune response in humans?	32:24
7. Should proposals include clinical trials? Would a phase II trial be under the scope of the topic?	43:46
8. Is there any particular viruses / vaccines targeting particular viruses that proposals should focus on?	47:35
9. Does the call expect proposals to develop and test vaccine candidates with good correlates for viruses identified by HERA?	53:56
10. Can proposals asking for 10 million budget apply?	54:47

HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response: Immunogenicity of viral proteins of viruses with epidemic and pandemic potential

Question	Link to answer
1. What can be the ideal number of partners involved for this proposal?	1:02:08
2. Proof-of-concept studies in humans of the vaccine candidate could be included - up to what clinical phase? Phase I? Phase IIa?	1:06:36
3. Can we choose more than one virus as model?	1:14:12

Destination 4. Ensuring access to innovative, sustainable and high-quality health care

Watch Presentation of Destination 4 Topics; Watch the whole Q&A on Destination 4

HORIZON-HLTH-2023-CARE-04-01: Maintaining access to regular health and care services in case of cross-border emergencies

Question	Link to answer
1. Does it have to be about COVID?	11:27
2. How many years may a project cover?	23:07

HORIZON-HLTH-2023-CARE-O4-02: Resilience and mental wellbeing of the health and care workforce

Question	Link to answer
1. Which of the topics of Destination 2 and Destination 4 that focus on the mental health of healthcare workers would provide a better fit for virtual reality to help healthcare workers reduce burnout?	6:35
2. The topic states that projects should avoid overlaps with ongoing calls or actions. Could you specify which calls or actions should or could be considered?	12:53
3. Are proposals that address homecare eligible or is the topic also funding proposals for clinical care (hospital or primary care)?	25:43
4. What TRL output would be acceptable for a multifaceted proposal tackling different problems/solutions?	31:32

HORIZON-HLTH-2023-CARE-04-03: Environmentally sustainable and climate neutral health and care systems

Question	Link to answer
1. Does 'infrastructure' (a term used in the guidance) relate just to buildings or also to organizational systems?	9:18
2. Are sustainable pharmaceutical developments considered to be within the scope of this topic?	15:40
3. Would the assessment of ongoing reforms in different countries be considered relevant under this call topic?	18:25

4.	Does this call support intervention development and implementation itself or should interventions be in place that are already funded?	[19:27](#)
5.	Will this topic include the sustainability of clinical pathways or models of care? (This could include the engagement of healthcare professionals.)	[24:43](#)
6.	Would there be room for a series of innovative technologies that reduce electricity consumption in hospitals and therefore reduce carbon dioxide emissions?	[27:30](#)
7.	Would the assessment of interventions or reforms which already exist be considered as within the scope of the proposals? {repeat of question 4}	[29:20](#)
8.	Would energy-efficient projects for hospitals be within the scope of the topic?	[33:47](#)

Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

[Watch Presentation](#) of Destination 5 Topics; [Watch the whole Q&A](#) on Destination 5

HORIZON-HLTH-2023-TOOL-05-01: Clinical trials of combined Advanced Therapy Medicinal Products (ATMPs)

Question	Link to answer
1. Are various cancer types, except rare cancers (under definition of "rare disease"), in the scope of this topic?	[25:57](#)

HORIZON-HLTH-2023-TOOL-05-03: Integrated, multi-scale computational models of patient patho-physiology ('virtual twins') for personalised disease management

Question	Link to answer
1. Is there a difference between virtual twin and digital twin?	[8:17](#)
2. Question of group of communicable diseases and/or non-communicable diseases with commonalities in different medical domains?	[13:08](#)
3. To what degree omics has to be included, in relation to personalized medicine?	[16:32](#)
4. Should proposal address all or several outcomes? It seems that there is discrepancy between presentation and the call text in Work Program.	[20:06](#)
5. Question about patients and citizen access – what is meant by "citizens and patients have access"?	[20:19](#)
6. Could you provide examples of outcome citizens and patients have access to validated virtual twin models? (call expected outcome)	[24:18](#)
7. Would you please clarify the procedures expected for the validation of multiscale computational models?	[29:34](#)
8. Question regarding stakeholders – is participation via focus groups sufficient or should patient associations be part of project proposal consortium?	[32:41](#)
9. Would it be advisable to include HTA (health technology assessment) expert in the proposal?	[35:39](#)
10. Do IT solutions for model visualization have to be CE marked?	[37:04](#)

11. Question on the concept of multi-organ approach- what is considered to be relevant for the call?	45:46
12. Is cancer in the scope of the call as disease?	50:54
13. What is meant by integrated standardized multi-scale models – are these to be developed by project?	55:04
14. Question on the groups of diseases for this call	56:50

HORIZON-HLTH-2023-TOOL-05-04: Better integration and use of health-related real-world and research data, including genomics, for improved clinical outcomes

Question	Link to answer
1. Question about the use of whole genome sequence data – what does it mean in practice?	10:37
2. Whole genome analysis- does the term genomics refer to the whole genome analysis? Is it compulsory to address genomics under this topic?	11:52
3. Question on real world health related data – does it refer to routinely collected clinical data or is it broader concept?	15:30
4. Would groups of diseases, i.e. dementia which encompasses several diseases, would be considered as the use case?	18:01
5. Does term clinical research data include existing open source medical data sets?	19:28
6. Is genomics data mandatory to the proposal, advantage of several other data formats?	44:39
7. Can an application to this call be look at rare disease, i.e. use for brain disorders?	47:18
8. What is the IP (intellectual property) condition of the technology solutions developed, e.g. is commercialization possible?	48:31
9. Who will have long term access to the data- will it be beyond project consortia?	51:24

HORIZON-HLTH-2023-TOOL-05-05: Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centred health and care delivery

Question	Link to answer
1. Do the proposals have to address all required activities to the same extent? (under the Call scope- "all of the activities")	27:13
2. Do you expect to see a pool of different technologies or to bring a single technology close to the market?	40:16
3. Could it be that the imaging system is already tested and implemented? (TRL levels)	41:05
4. What do workflows in surgery are supposed to cover?	47:52
5. Links to the European Health Data Space infrastructure	49:10
6. Which TRL is required or intended for this call? Is Quality Management System included?	52:04
7. Would multiple technologies validated and reaching TRL7 and integrated but not validated technologies would fit the scope?	53:22
8. Should all listed technologies be included, i.e. more are better?	54:13

HORIZON-HLTH-2023-TOOL-05-08: Pandemic preparedness and response: In vitro diagnostic devices to tackle cross-border health threats

	Question	Link to answer
1.	Is it better to have all areas covered under the scope or just few? (WP text - proposals should address several but not all areas under the scope)	34:28
2.	Is it allowed to contact members of JRC or would this generate conflict on interests?	38:37
3.	Question on JRC participation rules	42:05
4.	Do we have to address all threats in the same proposal?	42:55

HORIZON-HLTH-2023-TOOL-05-09: Developing a Data Quality and Utility Label for the European Health Data Space

	Question	Link to answer
1.	How does this topic support European Data Space proposal?	28:19

Destination 6. Maintaining an innovative, sustainable and globally competitive health industry

Watch Presentation of Destination 6 Topics; Watch the whole Q&A on Destination 6

General Question

	Question	Link to answer
1.	1. General tips from the moderator before closing the session	40:48

HORIZON-HLTH-2023-IND-06-01: Supporting the update of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU

	Question	Link to answer
1.	How should the HTA training program to be developed align to the HTA capacity building initiative under EU4health?	24:32
2.	Is there a required (estimated) time span for the implementation of the HTA training program to be developed?	33:42
3.	Is the participation of HTA bodies as part of the consortium required?	36:50

HORIZON-HLTH-2023-IND-06-02: Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space

	Question	Link to answer
1.	a) Should the consortium also produce EHDS strategic recommendations, or only technical solutions? b) Should SDOs be included in the consortium?	21:50

2. The text mentions the possibility of use of clinical studies - what type of clinical studies do you mean in this context (EHR Exchange Format)	28:30

HORIZON-HLTH-2023-IND-06-04: Modelling and simulation to address regulatory needs in the development of orphan and paediatric medicines

Question	**Link** to answer
1. HORIZON-HLTH-2023-IND-06-04/Modelling and simulation orphan and paediatric medicines. Should the target population be simultaneously pediatric AND rare?	10:35
2. HORIZON-HLTH-2023-IND-06-04/Modelling and simulation orphan and paediatric medicines. For a secondary use of real world data, is the informed consent needed?	11:52
3. Regarding HORIZON-HLTH-2023-IND-06-04: is the call limited to MEDICINAL products or does it also cover MEDICAL devices (SW and/or HW)?	17:58
4. HORIZON-HLTH-2023-IND-06-04 What does "mature computational models" means? From which point of view? Clinical application maturity?	19:23
5. IND-06-04 Should be the model be applied to the same disorders for which it has been originally developed?	27:30
6. IND-06-04 Should EMA and National Authorities be involved since the proposal development or is it sufficient to describe in the proposal the engagement process?	29:00
7. IND-06-04 Should be identified different disorder groups or just one disorder group applied to different computational models?	39:13

HORIZON-HLTH-2023-IND-06-05: Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs)

Question	**Link** to answer
1. Are combined ATMPs allowed in this topic? E.g. medicine plus a device.	38:36

HORIZON-HLTH-2023-IND-06-07: Development and harmonization of methodologies for assessing digital health technologies in Europe

Question	**Link** to answer
1. What does "digital health technology use case" specifically refer to? Is it about DHTs clusters/categories or specific applications?	9:18
2. Could the methodological framework adopt a lifecycle approach also addressing regulatory pathways or should these be left aside?	15:40
3. How would you imagine the robustness of developed methodologies to be assessed?	17:04
4. Text cites several DHT categories that may require differential assessment frameworks: should we focus on some or a single framework is preferred?	23:05

5.	Can the proponents use already collected data or does this call imply running clinical studies to collect data to address the aims? (edited)	26:35
6.	The moderator comments on JRC involvement on proposals to this call	31:48
7.	As we will propose methods for multiple assessment domains (clinical,privacy,..) can different use cases be identified to test methods for different domains	32:28
8.	Text mentions a framework to evaluate and monitor impact of the use as one of the outputs. This would be different from the assessment framework, right?	35:05

Cross cutting issues

[Watch Presentations](#) on Clinical studies, Social sciences and humanities, Gender equality provisions; [Watch the whole Q&A](#) on Cross cutting issues

General Questions

Question	Link to answer
1. Do all partners need a GEP, or only the coordinator?	21:12
2. When is the Gender Equality Plan needed? At proposal submission or Grant Agreement preparation stage?	21:50
3. Does one have to fill in a "clinical study template" for population-based cohorts or historical studies?	22:58
4. Broad definition often leads to having to deliver 3-4 clinical study annexes in one proposal. Guidance on when annex is necessary and when not?	23:30
5. Are there any study types that will not need a clinical study description - like for example - observational ergonomic studies, interview studies or similar?	24:08
6. Do all clinical centres involved in a project need to be project beneficiaries, or are there other ways to involve them?	25:06
7. Blind evaluation: how do we describe previous projects and work if one is not allowed to name organisations?	27:40
8. Do the SSH experts have to be scientists or can they be e.g. SEMs applying SSH expertise in a certain context?	28:35
9. Is the GEP mandatory also for hospitals?	29:45
10. What SSH disciplines are typically in Health projects?	30:23
11. Is the clinical studies template different for the calls in 2023 as it was in 2022?	31:17
12. Concerning gender balance in the overall proposal, how is a female:male ratio over 1 considered? Is a prevalence of female scholars appreciated or discouraged? (edited)	32:30
13. When our activity is very innovative and atypic, the blind application is hard to keep blind (since only one company is doing that). How can we do in this case?	33:34
14. In light of some Hungarian universities recently being cut off from EU funding, is it impossible to include one of them as a partner in a proposal?	34:47
15. Can you please give some examples what SSH could typically contribute to the r+d in a proposal?	35:33
16. What is the best method to find partners for a proposal?	36:55

17. Researcher table: Should you mention people here you do not yet know, but plan to hire?	38:23
18. Do third countries receive EU funding in the projects?	40:12
19. What is the status of the Association agreement with New Zealand and Australia?	42:01
20. Is the participation of low or middle income countries positively evaluated in the proposal evaluation?	43:35
21. When a disease is predominant in women and rare in men, is there a procedure to follow not to be downgraded?	44:34
22. Are UK registered NGOs still eligible to apply for funding?	45:39
23. Will the UK sign the Grant Agreement if project is granted? And, should we include UK budged in the total estimated EU budget requested?	47:06
24. Should countries from different regions of Europe (N; S, C, W, E) be consider is this a must?	48:52
25. Who counts as SSH expert? how about interdisciplinary experts that deal exactly with these questions? for example: Human computer interaction researchers.	49:16
26. An Australian entity can participate without EU funding but with NHMRC (Australian) funding?	50:11
27. Is it compulsory to have a specific partner dedicated to SSH, or possible that within one partner a strong expertise in SSH involved by the project is included?	51:01
28. If someone received funding as a co-applicant but changed institutions afterwards, do they have any rights to at least a part of the funding?	51:51
29. Can you participate in several proposals for the same topic?	52:46
30. Is there any requirement regarding the consortium composition (region composition) W Europe, S Europe, E Europe?	53:38
31. What does it mean for health the extension of the UK coverage of HE projects until the end of March only?	54:32
32. Any special requirements or extra rulings for private companies or startups participating in the consortium?	55:15
33. Can UK entities be coordinators in HE proposals during this transition stage? What are the directions then at GAP?	56:53